Biotech ipo market 2020. IPOs in 2020 and 75% in Q1 2021.

Biotech ipo market 2020. So how can you cultivate a strong brand image and ensure positive associations when consumers spot your logo? Writer and researcher Mario Natarelli talks through the essentials to building reliable relationships with customers. Following the recent news of Remegen's massive USD 515 million IPO in November 2020, we bring you the seven biggest biotech IPOs this year. This is despite the fact that biotechs have underperformed over the past few years. Jul 1, 2024 · The third was immune-mediated disease biotech Alumis, which downsized its plans for a $274 million IPO in the final days of June to eventually comprise $250 million spread across both an IPO and Feb 9, 2021 · 2020 stands out as one of the best years ever for biotech financing across the globe. dollars of capital through initial public offerings (IPOs), while they received some 14. - The Trump administration's plans to cut FDA budget and staff by 25%, combined with uncertainty over drug pricing policies, have created significant obstacles for the biopharma market. The Rise of SPACs: SPACs made up 53% of U. Oct 7, 2022 · The increasing receptiveness of public markets to IPOs from early-stage biotech companies also drove a spike in firms with preclinical cell- and gene-therapy programs. The largest—and first—IPO was CG Oncology's $380 million raise. In the Jan 20, 2021 · Of the 11 Hong Kong-listed biotech IPOs in 2020, 7 had lead candidates in phase I or phase II, whereas in 2019 and 2018 all Hong Kong-listed IPOs had lead candidates in phase III or later. With this kind of a start, 2021 may be scorching. Biotech companies are forced to license out some of their assets to support their pipeline developments. 5 billion. Apr 1, 2021 · Private biotech firms are awash with funding, raising record-breaking sums in 2020. We’ve seen stellar pricings and good after-market performance, with ten new offerings already this year. Introduction Biotech and pharma companies undertaking capital raisings can approach the world’s capital markets in various ways. Apr 30, 2021 · The great biotech acceleration Between 2019 and 2020, biotech saw double-digit annual growth in fundraising from VCs and deals such as partnerships, codevelopments, and joint ventures. Jul 28, 2025 · Licensing partnerships and R&D collaboration metrics M&A activity and transaction patterns IPO market performance and capital raised Investment focus areas in advanced therapies and technologies Download these reports to gain deeper insights into current dealmaking trends, and connect with our Startup Banking experts to learn more. Key reasons for the flourishing IPO market include: Increased investment: Venture capital investment into biotech has surged, providing firms the capital needed for public listing. The company showcased its flagship product MCS®-2, targeting the benign prostatic hyperplasia (BPH) market, which is projected to grow from $4. stock exchange. - All May 28, 2025 · “At some point, likely in 2026, we are going to have a normal biotech IPO market,” said Fenton, noting that there were about 30 to 40 biotech IPOs per year on average from 2017 and 2019, which Oct 7, 2024 · The IPO market is perking up and is open for strong stories. Jan 5, 2024 · The election doesn't change the biotech market’s positive direction - historically, it hasn’t. biotech companies raised some ten billion U. Jan 23, 2025 · The biotech IPO market in 2024 remained subdued, continuing the downward trend compared to the post-pandemic peaks. Compiled by editor Max Gelman. Oncology, neurodegenerative disease, and gene therapy dominated new listings in the life sciences. View information on the latest IPO's, expected IPO's, recent filings and IPO performance. Stock indices remained up through December. Private and public biotech funding, including global venture capital (VC) investments, deals, and IPOs, reached all-time highs in 2020. In addition to raising Mar 19, 2025 · Biotech Statistics - With 308 biotech developers and 53 suppliers as of 2023, Switzerland has demonstrated regular growth since 2005. Jun 18, 2025 · The 35th edition of the Ernst & Young LLP (EY US) Biotech Beyond Borders Report finds that the biopharma industry is currently in a challenging market. Apr 23, 2024 · Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet Mar 23, 2022 · Though last year was a rollercoaster for biotech IPOs, 2022 has comparatively leveled off as shares miss 2021’s signature spike. Mar 24, 2025 · However, the biotech IPO market has cooled significantly since its peak in 2020-2021. 2 billion U. 19 billion collectively. Aug 15, 2020 · The drug industry is shattering capital-raising records in 2020, as investors funnel money into pharmaceutical and biotech companies. When I began my career in venture capital in 2004, Oct 7, 2022 · The increasing receptiveness of public markets to IPOs from early-stage biotech companies also drove a spike in firms with preclinical cell- and gene-therapy programs. Jan 12, 2024 · A list of all the initial public offerings (IPOs) on the US stock market in the year 2024. Nov 17, 2022 · November 17, 2022 - As part of their growth strategy, private biotech and pharmaceutical companies often seek to raise capital through initial public offerings (IPOs). Mar 25, 2022 · Numbers of biotech IPOs and average amount raised, 2012–2021. Finer, along with the CEOs of Sep 23, 2020 · Currently, ~50% of the 2020 IPO class to date have market capitalizations floating >$1B. FDA Calendar, PDUFA Date Calendar, Biotech Company Screener and Database and much more Mar 3, 2025 · Explore how the biotech landscape is evolving in 2025, with advanced therapies, integrated CROs, and renewed funding shaping tomorrow’s breakthroughs. 4 billion). IRA legal challenges continue to make progress in 2024 – which creates pressure to rewrite the law. Jun 16, 2025 · The narrative among biotech management and their investors used to be to work toward an IPO and sustainability, with M&A a background option. Jan 26, 2024 · For example, the 2013 class of IPOs—which followed a year when only 10 life science companies went public—included the likes of gene therapy frontrunner bluebird bio, Agios Pharmaceuticals and Dec 3, 2021 · The global biotech sector is flourishing. Mar 18, 2024 · A brief history of the recent biotech industry fluctuations What are the reasons behind this uptick in biotech investments in the US? IPOs drive biotech investment revival in the US Continued caution around early-stage biotech companies Influence of M&A activity on the US biotech investment landscape Guarded optimism and recovery for the Nov 30, 2020 · Investor interest in biopharmaceuticals has surged and 2020 is on track to post the highest number of biotech IPOs in five years. IPO TRACKER A real-time look at every biotech IPO filed and the amount raised in all the world's indexes. Jan 20, 2021 · Last year was a record number of IPOs in the biotech industry, with 81 raising $13. 6 billion in the process (for contrast, the previous 10 years saw the biotech IPO market raise a total of only US$24. With 50 IPOs raising $8. 1 Trillion in total market capitalization as of April 2021, including 7 companies large enough to warrant inclusion in the Nasdaq-100 Index. There was a marked uptick in the number of early-stage platform technology companies (as opposed to asset-focused firms). Dec 22, 2020 · The 2020 IPO market saw a slowdown in March and a frenzy of deals in December. Apr 17, 2020 · The biotech IPO market in 2020 remains strong, despite the volatility and COVID headwinds. Jan 24, 2025 · 2024 saw a healthier IPO market than 2023, with activity triggered by M&A that occurred in the back end of '23, Morgan Stanley's Chirag Surti said. Real-time information on initial public offerings (IPO's) by MarketWatch. Feb 15, 2024 · The public equity markets for biotech struggled during the year, with fewer than 50 initial public offerings (IPOs), a drop in follow-on offerings, and debt financing virtually non-existent. Mar 22, 2021 · Biotech IPOs and M&As have boomed over the last year. But the future is uncertain: the public market and IPOs are down, but venture funding is still near all-time highs, and there have never been as many innovative companies and technologies. Jan 31, 2025 · In their wide-ranging conversation, the industry leaders spoke about the types of biotechs that debuted on the public market in 2024, the keys to success for an effective IPO and what to expect These IPOs often reflect not only the companies' growth but also the overall market sentiment towards biotech. 1 billion — an increase of 16% from Q2 2024 — investor optimism surged late in the quarter, particularly in the technology, media and telecommunications sector, which accounted for 24% of deals. 43 billion CymaBay Therapeutics buy. Despite the COVID-19 pandemic, or in some cases because of it, public investor capital has flooded into biotech companies entering the global public markets. Includes IPO prices, dates, total returns and more. Discover the biotech industry's explosive growth from 2020-2030 with 50+ key stats on market expansion, and emerging innovations. 1). Trends in the IPO market are reflecting a move back to more traditional investment standpoints for biotech investors, with most IPOs being carried out by companies with mid- to late-stage assets that have been somewhat de-risked. Sep 21, 2020 · In the excitement of today’s biotech IPO market, and the bullish period since 2013, it’s almost hard to remember how painful the equity capital markets were back in the day. 4 days ago · Detailed information the last 200 IPOs (initial public offerings) on the stock market. The boom was driven by a mix of factors, including strong investor enthusiasm, breakthroughs in biotechnology, and the rapid development of COVID-19 vaccines and treatments. Biotech financing went off the charts, with initial public offerings (IPOs), follow-on offerings and private Feb 14, 2025 · The worst of this storm may be over, as the 24 biotech IPOs conducted last year are a tick up from 2022 and 2023. However, value creation is not guaranteed. What Investors Are Looking For Investors are prioritizing quality over quantity in clinical data and seeking companies whose leadership teams have proven track records, which are crucial for Dec 31, 2020 · According to a report by Biopharma Dive, a whopping 71 biotech companies collectively raised more than $16 billion through initial public offerings (IPO) in 2020, setting a new record for the sector. But there are risks to be aware of. 9 billion for an increasing share of small-cap biopharma companies. Public market conditions have meaningfully improved with the Fed’s rate cut as evidenced by increased IPO activity, healthy follow-on volume, and several SPAC merger announcements which have been extremely limited in the past two years. The average fully diluted valuation at IPO of companies that went public from 2018-2021 was $827M (median Apr 3, 2024 · The biggest M&A deal of Q1 was Gilead's $4. The next waves of science and innovation are on the horizon, and the bio-revolution is well underway. 6 billion across Q2 and Q3 combined, as Jul 7, 2023 · The China IPO market has remained open in 2023 to commercial stage pharma companies but biotech offerings are slim. 1 billion May 28, 2025 · The 2020-2021 pandemic period saw approximately 150 biotech companies go public in just two years, creating a bubble reminiscent of previous biotech IPO surges like 1991’s record of 35 IPOs 1. A list of all the initial public offerings (IPOs) on the US stock market in the year 2023. The class of 2020 biotech IPOs will go down as one of the most buoyant in history, with the leading 10 raising a massive $3. Jun 11, 2025 · The biotech boom, driven by demand for new treatments and sustained by a surge of capital investment, offers new opportunities for investors. May 13, 2020 · How Did Biotech Do in Previous Crises? From March 2009 until mid-February 2020, the US stock market and economy had experienced almost 11 years of consistent growth with the S&P500 generating a total return of 529% 1, equivalent to an 18% compound annual growth rate. the leader in biopharma IPOs. The public biotech market rebounded in late 2023 in anticipation of the Fed pivot and an uptick in M&A, though it remains suppressed relative to 2020-2021 levels. 2020 biotech IPOs shatter all the records Despite the COVID-19 pandemic, or in some cases because of it, public investor capital has flooded into biotech companies entering the global public After a busy IPO period during the heights of the coronavirus pandemic, the window for biotech companies looking to go public has remained mostly shuttered over the past few years, with only a handful of companies braving the public market waters. Apr 8, 2020 · Keros Therapeutics has braved a turbulent market to pull off an IPO, hitting the top end of its price range and selling 20% more shares than originally planned. The biotech IPO market has cooled over the past few years in the wake of historical levels of issuance and proceeds in 2020 and 2021 (Figure 1). Comprehensive suite of tools for trading and investing in biotech stocks. Jul 25, 2025 · In Q2 2025, the US IPO market experienced a notable recovery after initial headwinds from tariffs and market uncertainties. We’ve seen stellar pricings and good after-market performance, with ten new offerings already this year Jun 18, 2025 · The 35th edition of the Ernst & Young LLP (EY US) Biotech Beyond Borders Report finds that the biopharma industry is currently in a challenging market. Market Strength: Biotech IPOs raised $14 billion through 74 deals in 2020, making the U. We’ve seen stellar pricings and good after-market performance, with ten new offerings already this year 2 days ago · For example, 2024’s biopharma IPO market began promisingly with $3. Notably, six of the seven companies are from China, pointing to the massive growth of the Chinese biotech market. Even so, the road to the public markets remains exceptionally fraught and energy-consuming. Business Insider spoke with top venture capitalists about why Feb 6, 2025 · U. Oct 1, 2021 · As of the end of August, there have been 71 biotech IPOs in the United States raising some $12. Apr 25, 2024 · After a prolonged slump, biotech IPOs are starting to gain steam. Despite COVID-truncated virtual roadshows and book-building processes, issuers have been able to garner robust market interest. May 11, 2022 · The biotech IPO boom of 2020 and 2021 saw 158 companies enter the public markets. Here’s what investors need to know about this year’s cooler market and the lessons learned from 2021’s top earners. Biopharma deal and funding activity in 2024 concluded with robust venture investments, increased upfront payments from licensing and modest growth in the IPO asset class. We define biotechs as developers of new prescription medicines. It also saw triple-digit growth in IPOs (Exhibit 2). New Oct 10, 2024 · During the heights of 2020-21, 131 and 154 biotech IPOs were completed respectively , compared to 17 by the end of Q3 2024. Oct 10, 2024 · During the heights of 2020-21, 131 and 154 biotech IPOs were completed respectively, compared to 17 by the end of Q3 2024. As the global market rebounds, these firms are capitalizing on the opportunity to go public, positioning themselves for growth and greater visibility in a competitive industry. Jan 12, 2022 · A few takeaways: Biotech venture funds have benefited from a very active IPO market. With both the number and proceeds of biotech IPOs reaching all-time highs, it’s clear that the market is betting on biotech. Through an initial public offering (IPO), listing either in its home jurisdiction or cross-border, biotech and pharma companies can access major global finance hubs and capital from a deep pool of investors around the world. The upsized IPO gives Keros the Jun 29, 2021 · Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021. Recent biotech IPO market reflections The biotech IPO market has cooled over the past few years in the wake of historical levels of issuance and proceeds in 2020 and 2021 (Figure 1). Oct 4, 2021 · In 2020, 71 biotech IPOs of at least $50 million — the cutoff for BioPharma Dive’s database — pulled in roughly $15 billion combined, a number that nearly tripled the totals of 2019 ($4. Mar 14, 2025 · Dan Cocks, MD of Healthcare Equity Capital Markets, and Maneet Singh, MD of Healthcare M&A, discuss market trends and what’s driving deal making in biotech and pharma. – decreased significantly. Here are 10 pharma and biotech companies that went public in 2025. Now, VCs are more up-front about their tailoring strategy. Aug 14, 2025 · In 2020, over 100 biotech companies went public, making it one of the busiest years for IPOs in the industry. It was 120. 9 billion across 10 biopharma IPOs completed on NASDAQ and NYSE in H1 2024 with 3 of these in Q2. In this study, we built a database of biotechs that underwent an IPO in the first half of 2021. Biotech companies and life sciences leaders are managing uncertainty and preparing to bounce back across the biotechnology landscape. However, the traits associated with biotech startups obtaining recent IPOs have not been reported. M&A: Biopharma M&A saw 26 acquisitions in Q2 2024 totaling over $17. Discover the latest trends in biotech IPOs and pharma M&A deals. In 2022 and 2023, there were only 22 major VC-backed IPOs on US exchanges. Good customer relationships are essential for brand growth. The average Mimicking the IPO market (more below), crossover rounds by the top public biotech funds have also decreased to a range of roughly 10 to 20 per quarter (as compared to nearly 60 in Q1 of 2021). Increasing Jan 12, 2022 · The prolific biotech IPO market was robust in 2020. “It’s not for the faint of heart,” said Jeffrey Finer, CEO of Septerna, a San Francisco area drugmaker that in October raised $288 million from an IPO. 7 billion). Melanie Senior reports. Fast forward to today: How has the landscape evolved over the past four years? Feb 28, 2022 · Biotech from bust to boom February 28, 2022 The last ten years have seen biotech enjoy the biggest and most durable boom in the industry's history. While 2020 and 2021 saw a surge in listings, fueled by pandemic-related optimism and low interest rates, the subsequent market correction has forced companies to adapt. Laura DeFrancesco and Riku Lähteenmäki 154 R&D-driven biotech companies that went public last year represent the largest number ever — even higher than 2020’s bonanza of 131. In the private markets, biotech startups are riding the AI wave in drug discovery to harness large datasets: Insitro, Valo and Tessera Therapeutics are among those deploying machine learning for Mar 6, 2025 · That trend has continued in 2025. The biotech IPO market collapsed after the Fed's rate hike campaign. To help understand where the market may go from here, this Jan 27, 2025 · The suspension of IPO approval lessens the chances of biotech startups seeking funds from the public market. 6 billion in total funding in Q1 – the highest in several years – but fell to $1. dollars) Oct 26, 2023 · In 2020 and early 2021, the success of Moderna and BioNTech in developing highly effective vaccines for COVID-19 drove a surge of investment from all corners of the market into biotech. Jan 19, 2022 · A list of all the initial public offerings (IPOs) on the US stock market in the year 2022. S. 7 billion, compared with 77 initial public offerings in all of 2020 that raised over $17 billion. 5 years from Series A (compared to 3+ years from Series A to IPO in 2018), and less than one year from Series B. Jun 6, 2023 · Biotech financing hit a rough patch: In 2022, all types of biotech financing – venture capital investment, debt financing, IPOs, follow-on, etc. In the second half of 2020, we saw enormous raises from companies like Relay Therapeutics ($400M) and Legend Biotech ($423M). IPO numbers boom, though average size can’t match 2020. The S&P 500 and NASDAQ are back at record or near-record levels, so investors looking for Mar 14, 2025 · Dan Cocks, MD of Healthcare Equity Capital Markets, and Maneet Singh, MD of Healthcare M&A, discuss market trends and what’s driving deal making in biotech and pharma. COVID-19 vaccine success stories like the Pfizer and BioNTech partnership helped highlight the biotech industry’s significant impact in advancing healthcare. The total Sep 12, 2024 · Three biotechs raise $700M in rare burst of IPO activity Bicara Therapeutics, Zenas BioPharma and MBX Biosciences all priced initial public offerings Thursday in the busiest week for biotech stock sales since February. However, the IRA doesn’t get fixed until after the election – and it’s not a slam dunk that it happens even then. In 2020, the sector recorded just Sep 10, 2025 · For this database, BioPharma Dive includes biotech companies that raised funds in an initial public offering on a U. Nasdaq’s market dominance in attracting biotech IPOs over several decades has resulted in an overall market share of 98% of current listings representing $1. Aug 6, 2020 · What can biotech companies expect to see regarding the IPO market in the coming months, as the coronavirus crisis continues? Our experts weigh in. Sixty-six percent of them had products and platforms in preclinical, or Phase I, development (Exhibit 5). Rising interest rates, investor caution, and underperforming public biotech stocks have made IPOs a less reliable exit strategy. This was an impressive streak until the coronavirus pandemic shut down non-essential activity and thrust the United States and Jun 25, 2025 · Biotech funding challenges: VC, IPOs, and the importance of industry partnerships While there are some signs of recovery, the pharmaceutical funding market remains volatile, with potentially detrimental effects for early-stage biotechs lacking the right partner to see them through clinical development. Jan 27, 2025 · Top global biotech companies selection based on market cap 2025 Select top global biotechnology companies based on market capitalization as of 2025 (in billion U. 7 billion) and 2018 ($5. 4% higher than the 480 IPOs in 2020, which was also a record. The MedTech and BioPharma IPO landscape has been volatile but may be looking to rebound as we look ahead to 2025. Globally, 307 SPAC IPOs were completed in Q1 2021. Biopharma Q1 2025: Big Private Deals, Cautious IPOs, and Global Growth Venture investments continued their larger-but-fewer theme, and licensing transactions posted larger potential deal values with a larger share of upfront payments for later-stage programs. Initial public offerings (IPOs) had a banner year, with >73 life Jul 8, 2021 · 2020 will be remembered in biotech—but not just for the response to the pandemic. Mar 17, 2025 · - Only five biotech companies raising more than $50 million have gone public in 2025, following 18 IPOs in 2024, representing a dramatic decline from the pandemic-era peak of 150 companies over 2020-2021. Among these, gene-editing 5 days ago · The biotech IPO market has experienced significant volatility in recent years. This . Biotech brought steady capital markets work to life sciences lawyers. Aug 18, 2024 · Biotech funding nears pre-2020 levels; platform firms face scrutiny as M&A activity targets late-stage assets. In each year since 2020, the proportion of biotechs worth $500+ million at IPO has been greater than any year prior to 2020. Nov 8, 2024 · By Ana Mulero November 6, 2024 With climbing biotech M&A and IPO activity following the post-pandemic slump, experts offer insights on maximizing value and otherwise capitalizing on exit opportunities. The pandemic has created a new roadmap for going public. In our Sep 4, 2025 · Pharma and biotech IPOs in 2025 offer novel investment opportunities. Though it’s a moribund IPO market in Europe, biotech companies may be best placed to break the mould here (considering the strong performance of their US counterparts this year). Dec 13, 2024 · Historically, 50 is the annual average benchmark for biotech IPOs. Nov 7, 2024 · Granted, the time to exit isn’t as quick as we see in other sectors: older biotech companies launched in the 90s are being scooped up by larger competitors too. When I began my career in venture capital in 2004, Feb 15, 2021 · 2020 was a record year for biotech IPOs—and that trend is continuing in 2021. Jul 22, 2025 · Jyong Biotech (NASDAQ:MENS), a Taiwan-based biotechnology company, marked two significant milestones: its Nasdaq IPO bell ringing ceremony on July 2, 2025, and participation in the BIO 2025 International Convention from June 16-19 in Boston. IPOs in 2020 and 75% in Q1 2021. Erasca reeled in one of the top private rounds of 2020 via an extended $236 million series B, and the cancer-focused biotech repeated itself in the public markets with an IPO that splashed into The biotech IPO market collapsed after the Fed's rate hike campaign. dollars in risk capital. To date, this year’s four biotech IPOs have averaged an initial market cap of $964 million, including three valued at $500+ million. Explore key drivers, major acquisitions, and what’s shaping the industry’s growth in 2025. IPOs: $1. There’s still an air of caution about today’s market. The S&P 500 and NASDAQ are back at record or near-record levels, so investors looking for Jan 1, 2022 · In 2020, 74 biotech startups went public through an initial public offering (IPO) and 60 went through the IPO process in the first six months of 2021. Jun 30, 2021 · A blistering IPO pace continues, with some caveats Despite a once-in-a-century pandemic, 2020 was a stunning year for biotech IPOs, both in terms of the number of offerings and the total amount raised. However, overall M&A activity declined despite higher deal medians. 4. Sep 12, 2023 · In 2022, the initial public offering (IPO) window for biotech companies remained closed throughout the year, with the smallest number of new companies in almost a decade (Fig. We saw the equity follow-on market open up after Labor Day with guns blazing – only to slow down in the last three weeks of September. Mar 27, 2024 · The upswell in IPOs has the potential to drive more drug companies to explore a public listing, according to PitchBook’s Q4 2023 Biopharma Report. High pricing power and strong go-to-market capabilities by international companies lead to the greater success of the pipeline. Sep 16, 2025 · The biotech sector is experiencing a remarkable surge in initial public offerings (IPOs), particularly in Hong Kong, where innovative companies like Ark Biopharmaceutical and Atom Therapeutics are making headlines. The biotech build Biotechnology funding, deals, and IPOs reached the highest levels worldwide in 2020, with venture-capitalist (VC) funding for biotech companies up more than 80 percent year-over-year, and IPO values increasing by more than 180 percent. This is changing as Laekna went public last week on the Hong Kong exchange and this week Kelun Biotech is going public. Mar 4, 2024 · Toward the end of 2023, however, deal activity in the life sciences industry showed renewed life, with both an active middle market for M&A dealmaking and a modest uptick in IPOs and follow-on opportunities in the public equity markets for biotech companies. Jan 7, 2021 · There were 1,035 IPOs on the US stock market in 2021, an all-time record. More than half of this year’s biotech class are working on novel cancer treatments, extending a multi-year trend, says Sonnier. The biotech IPO market fell 93% from 2021, and an estimated 29% of public biotechs in the US and Europe had less than one year of cash on hand. During 2020 and 2021, US and European biotechs carried out an unprecedented 216 IPOs, raising US$30. Apr 12, 2024 · Proceeds from biotech IPOs during the first three months of 2024 matched levels seen in the first quarters of 2019 and 2020, BioPharma Dive data show. The number of IPOs dropped from 38 in 2023 to 28 in 2024, displaying both investor and company caution amid challenging market conditions for public offerings. A list of all the initial public offerings (IPOs) on the US stock market in the year 2020. Biopharma startups are going public 2-2. Jun 6, 2025 · Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech companies to IPO in 2020. However, venture-backed private companies, particularly in the biotech and biopharma sectors, are increasingly considering the SPAC route as an attractive alternative to go public. Jun 25, 2020 · Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 – so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax. Jun 16, 2023 · In 2020, U. Explore this and other trends in the biotech market to get ahead of industry shifts. Find out how. In the current market environment, we believe investors have become more discerning about the valuation, differentiation, and maturity of biotech companies and moved away from a momentum-driven approach. trhsd lxpqm slkvh zhqash nzgvaak llpv brdmmn khmqs tpi phbmth